Connect with us

Hi, what are you looking for?


Person with HIV ‘cured’ after bone marrow transplant; donor does not carry CCR5-delta 32 mutation

Five individuals are considered as having probably been cured of HIV infection after receiving a bone marrow transplant taken from donors with the rare genetic mutation CCR5-delta 32. This new case had transplant taken from a donor who does not carry the CCR5-delta 32 mutation.

Photo by Yanal Tayyem from

HIV treatment milestone.

This February, the IciStem consortium – which includes Asier Sáez-Cirión’s team at the Institut Pasteur – published details in Nature Medicine of a third case of HIV remission after a bone marrow transplant, involving the Düsseldorf patient.

A total of five individuals (the Berlin, London, Düsseldorf, New York and City of Hope patients) are now considered as having probably been cured of HIV infection after receiving a bone marrow transplant. In all these cases, the bone marrow was taken from donors carrying the rare genetic mutation CCR5-delta 32, which is known to provide cells with natural protection against HIV.

At the International Conference on HIV Science, Asier Sáez-Cirión, head of the Institut Pasteur’s Viral Reservoirs and Immune Control Unit, and Professor Alexandra Calmy, MD, PhD and HIV/AIDS Unit Director at the Geneva University Hospitals (HUG), presented a case of HIV remission following a bone marrow transplant performed as part of the patient’s cancer treatment.

The significance of this patient monitored in Geneva at the HUG, whose case is being examined jointly by the Institut Pasteur, Institut Cochin and the IciStem consortium, lies in the fact that the transplant was taken from a donor who does not carry the CCR5-delta 32 mutation.

Therefore, unlike the cells of other individuals who are considered to have been cured, this person’s cells remain HIV-permissive. Despite this, the virus was still undetectable 20 months after antiretroviral therapy was discontinued. These findings will be presented orally in Brisbane, Australia on July 24, 2023.

The individual, whose circumstances will be outlined in the presentation, has been living with HIV since the early 1990s and received antiretroviral therapy from the outset. In 2018, he underwent a stem cell transplant as treatment for a particularly aggressive form of leukemia. One month after the transplant, tests showed that the patient’s blood cells had been entirely replaced by the donor’s cells, and this was accompanied by a significant reduction in the number of HIV-infected cells. Antiretroviral therapy was gradually reduced and permanently discontinued in November 2021.

Tests performed over the 20 months following therapy discontinuation found no viral particles, no latent viral reservoirs or any increase in the immune response against the virus in the individual’s body. Although this evidence does not rule out the persistence of the virus in his body, the scientific team can nevertheless classify the “Geneva patient” as a case of remission from HIV infection.

“What has happened to me is wonderful and magical – we can now focus on the future,” the Geneva patient.

“Although this protocol is not applicable on a large scale due to its aggressiveness, this new case provides unexpected insights on mechanisms of eliminating and controlling viral reservoirs, which will play a key role in devising curative HIV treatments,” Asier Sáez-Cirión, Head of the Institut Pasteur’s Viral Reservoirs and Immune Control Unit.

Advertisement. Scroll to continue reading.

“Through this unique situation, we are exploring new avenues in the hope that HIV remission or even cure will one day no longer be a one-off occurrence,” Alexandra Calmy, HIV/AIDS Unit Director at the Geneva University Hospitals.


Like Us On Facebook



Drugs that prevent HIV infection have evolved, but new research shows the standard option is still top with patients.


On the pre-intervention survey, 7% of study participants said they were not considering starting PrEP within the next month, and 86% said they were...


Pre-exposure prophylaxis with EFdA administered orally can efficiently prevent HIV acquisition via the penis.


In 2015, Teleperformance reinforced an HIV policy within the workplace. This was succeeded by a readily available HIV testing in different TP sites across...